AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02997995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune-attractant
Description: The first cohort patients will receive tremelimumab (3 mg/kg, single infusion) as immune-attractants combined with exemestane (25 mg daily).
Study NCT01192802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole
Description: 1 tablet of 400 mg of albendazole per day for three consecutive days
Study NCT01192802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole
Description: single 1 tablet of 400 mg of albendazole
Study NCT01192802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole
Description: 1 tablet of 400 mg of albendazole per day for two consecutive days
Study NCT03963271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECG-Imaging
Description: A body surface potential mapping and a cardiac + low dose CT-scan.
Study NCT03665025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immediate implant using mixed allograft and xenograft
Description: immediate implant using mixed allograft and xenograft in anterior area to fill jumping area
Study NCT01681355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula
Description: Standard cow's milk based infant formula with added prebiotic oligosaccharides, and a modified fat blend and protein composition
Study NCT00943072 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye 2.0mg
Description: Monthly intravitreal injection out to the Week 24 Primary endpoint
Study NCT00943072 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Monthly sham intravitreal injection out to Week 24 Primary Endpoint
Study NCT02933450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patiromer 25.2 g
Description: Single dose of Patiromer 25.2 g
Study NCT01505764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anamorelin HCl
Description: 100 mg tablets; oral administration every day for 84 days, at least 1 hour before the first meal of the day.
Study NCT01505764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets identical in appearance to active tablets; oral administration once a day for 84 days, at least 1 hour before the first meal of the day.
Study NCT03774056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-1119
Description: oral
Study NCT04475042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 10mg od
Study NCT04475042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01039129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Cholecystectomy
Description: An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus.
Study NCT01039129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Appendectomy
Description: An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus
Study NCT01039129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Peritoneoscopy
Description: A diagnostic peritoneoscopy with or without biopsy for any indication
Study NCT02603666 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fibroscan
Description: Ultrasound by specific wavelength developed for elastography, repeated measures according to the manufacturer's instructions.
Study NCT00522236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008
Description: A single 0.5mL dose of Novartis adjuvanted subunit influenza vaccine, Fluad contained 45μg of viral hemagglutinin, composed of 15μg of the three influenza antigens:~* A(H1N1) strain: IVR-145 (Solomon Island/3/2006 - like strain)~* A(H3N2) strain: NYMC X-161B (A/Wisconsin/67/2005-like strain)~* B strain: (B/Malaysia/2506/2004-like strain) in accordance with the recommendations of the World Health Organization, the EU and the national Regulatory Agencies for the 2007/2008 season.~The vaccine is a milky liquid, and was packaged in ready to use, single dose syringes.~A single dose of FLUAD vaccine was administered intramuscularly, preferably in the deltoid muscle of the non dominant arm.
Study NCT00336830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MD-endorsed Cardiac Rehabilitation referral
Description: Note to patient with general description of the Cardiac Rehabilitation program with signature and strong recommendation from attending physician.
Study NCT00336830 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cardiac Rehabilitation referral
Description: Note to patient with general description of the Cardiac Rehabilitation program without signature or recommendation from attending physician.
Study NCT03310489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digitalized cognitive-behavioral intervention for anxiety
Description: An internet-based CBT, including telephone coaching
Study NCT03310489 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation about anxiety
Description: Psychoeducative material about anxiety in internet
Study NCT02052076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal pattern
Study NCT02052076 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Meal pattern
Study NCT02223702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 500 mg, 3 times per day for 7 days
Study NCT02223702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 500 mg, 3 times per day, for 7 days
Study NCT02223702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg, once in a day for 7 days.
Study NCT01754402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered intravenously over 1 hour (if using Treanda) or over 10 minutes (if using Bendeka) on day 1, every 28 days for 12 cycles.
Study NCT01754402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered once daily orally (PO) on days 1-21, every 28 days until disease progression or death.
Study NCT02997995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (lymphocyte activation) will be administrated at a dose of 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months
Study NCT02997995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: After three weeks (+/- 3 days) of immune-attractants, a tumor biopsy will be done. Patients who present >10% CD8+ cells in the tumor after 3 weeks will receive the Durvalumab
Study NCT01754402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered weekly orally or intravenously on days 1, 8, 15, and 22 every 28 days until disease progression or death. After 6 cycles of treatment, the dose may be reduced to 20mg at investigator's discretion. For subjects ≥ 75 years of age, the starting dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each 28-day treatment cycle.
Study NCT03896256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine infusion
Description: Ketamine will be used in subanesthetic doses for patients with refractory chronic migraine to see if it improves pain after a 5-day continuous infusion.
Study NCT00822926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Subcutaneous injection of saline into scar tissue
Study NCT01204008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conservative discectomy
Description: a smaller incision with removal of the disc fragment with little invasion of the disc
Study NCT01204008 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aggressive discectomy
Description: a large open incision with aggressive removal of the disc fragments and curettage of the disc space
Study NCT04206280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of a pedometer following surgery
Description: Subjects in the study group will receive a pedometer with graduated step count goals as discussed in arm description.
Study NCT04206280 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Subjects in the control group will be counseled on the importance of ambulation during their pre-operative visit.
Study NCT04502940 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow Cytometric analysis
Description: Blood samples will be taken from the patients with biliary pancreatitis and healthy volunteers to perform flow-cytometric analysis and to determine lymphocyte subgroups
Study NCT04142983 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adacel
Description: 0.5 mL, Intramuscular
Study NCT00852293 — intervention group
Intervention type: OTHER
Intervention: A blood test
Description: A blood test of about 5ml of blood will be taken to determine Chitinase 3 like-1 protein levels.
Study NCT03445078 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: selenium supplementation
Description: administration of selenium-rich corn powder 20g/d offering selenium 100μg/d
Study NCT03445078 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: selenium supplementation
Description: administration of selenium-rich corn powder 20g/d offering selenium 100μg/d
Study NCT03445078 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ordinary corn powder
Description: ordinary corn powder,20g/d(selenium contain \<0.5ug/20g).
Study NCT03445078 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: ordinary corn powder
Description: ordinary corn powder,20g/d(selenium contain \<0.5ug/20g).
Study NCT00138736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannan Binding Lectin (MBL)
Study NCT00138736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannan Binding Lectin
Description: MBL dose at a twice weekly dose interval (3 or 4 days):~0.2 mg/kg, for a 3-day interval; 0.3 mg/kg, for a 4-day interval
Study NCT01531114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Description: Patients will be randomized to this arm to receive loading dose of ticagrelor
Study NCT01531114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel
Description: Patients will be randomized to this arm to receive loading dose of prasugrel
Study NCT05628714 — intervention group
Intervention type: OTHER
Intervention: Patient decision aid for patients with superficial basal cell carcinoma
Description: An online WebApp
Study NCT03723629 — intervention group
Intervention type: OTHER
Intervention: No intercention
Description: No intercention
Study NCT03187600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mucosa/submucosa Pharyngeal Flap
Description: Included in study arm description
Study NCT03187600 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Pharyngeal Flap
Description: Included in study arm description
Study NCT05315466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment
Description: Analgesics, anti-inflammatories, muscle relaxants, physical therapy, Global Postural Rehabilitation, magnetic therapy, laser therapy, transcutaneous electrical nervous stimulation (TENS), massage, cognitive-behavioral therapy and all those procedures that can bring benefit to back and leg pain.
Study NCT05315466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment for spinal stenosis
Description: Decompression of nerve structures by laminotomy or laminectomy and posterior lumbar fusion if stabilization of the column is required.
Study NCT04188184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: received topical 1 gram of TXA diluted in 200 ml of normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
Study NCT04188184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: received Epinephrine 1 mg diluted in 200 ml normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
Study NCT02491294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School
Description: students receive Cooking With Kids (CWK) - Colorado cooking \& tasting lessons, SPARK active recess, and Cafeteria Connections
Study NCT01788358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/8 mg, orally once daily
Study NCT01788358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/16 mg, orally once daily
Study NCT01788358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/16 mg, orally once daily
Study NCT01788358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Description: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/32 mg, orally once daily
Study NCT03546868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FSPG
Description: Patients will receive 200 MBq of \[18F\]FSPG and undergo PET/CT for assessing disease activity in inflammatory bowel disease
Study NCT02429180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: ReTrain: an exercise-based functional training programme comprising two phases: (1) weekly supervised sessions; (2) monthly drop-in sessions, plus home-based exercise in each phase.~* Week 1: one-to-one consultations with trainer to introduce programme, assess individual's concerns and capabilities, introduce and negotiate initial goals~* Weeks 2-11: bi-weekly 90 minute group class with group-based activities and one-to-one coaching, based on ongoing goal negotiation review and progression.~* Week 12: one-to-one consultations with trainer to review goals and plan ongoing unsupervised exercise programme~* Weeks 13-24: monthly drop-in sessions for one-to-one consultation, support and progression.
Study NCT04085900 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood and saliva
Description: Collect blood and saliva samples from participants
Study NCT04085900 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: P85-Ab, EBNA1-IgA, VCA-IgA and EBV DNA
Description: Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants, and detect EBV DNA for all male participants and P85-Ab positive female participants.
Study NCT04085900 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fiberoptic endoscopy and biopsy
Description: Screening participants will refer to fiberoptic endoscopy and biospy
Study NCT02727439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Exhausting Exercise (AE)
Description: A single progressive rowing training to maximal exhaustion (AE).
Study NCT04740138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavioral Therapy Skills + Parent Training
Description: The DBT/Parent training group intervention is a novel integration of three evidence-based treatments (i.e. DBT Skills, Parent Management Training (PMT), and Emotion Coaching (EC)). The DBT Skills portion of each session follows the DBT Skills Training Manual Second Edition and DBT Skills Training Handouts and Worksheets Second Edition. DBT Skills portions cover the four modules of traditional DBT Skills: mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness.~PMT portions of the intervention cover: praise, positive interactions and parental attention, reward systems, effective commands, use of consequences, and problem solving. EC portions of the intervention cover: psychoeducation on children's emotional development, teaching children to identify and label emotions, validation of children's emotions, handling children's negative emotions, fostering children's positive emotions and parental modeling of emotion regulation and expression.
Study NCT03126344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: King Vision video laryngoscope
Description: nasal intubation using King Vision video laryngoscope Device after general anesthesia induction
Study NCT03126344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath MAC video laryngoscope
Description: nasal intubation using McGrath MAC video laryngoscope Device after general anesthesia induction
Study NCT03126344 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: nasal intubation using Macintosh laryngoscope Device after general anesthesia induction
Study NCT00490529 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CpG-MCL vaccine
Description: CpG-MCL vaccine is a vaccine prepared by co-culturing cells from the participant's mantle cell lymphoma suspension with 3 mcg/mL PF-3512676, then irradiated to 200 Gy. 1 x 10e8 CpG-MCL cells will be given as a subcutaneous injection.
Study NCT00490529 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-3512676
Description: PF-03152676 is a synthetic immunostimulatory, single-stranded oligodeoxynucleotide (oligo-DNA) moledule containing unmethylated cytosine and guanine (CpG) motifs. PF-03512676 acts as an agonist of human Toll-like receptor 9, leading to activation of antigen-presenting cells and a cascade of antitumor immune reactions.
Study NCT00490529 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaccine-primed T-cells
Description: Vaccine primed T-cells are the post-vaccination leukapheresis harvest of peripheral blood mononuclear cells. Each collection is approx 1 x 10e10 CD3+ T-cells.
Study NCT00490529 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplant (HSCT)
Description: Regular medical procedure
Study NCT00490529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m² by infusion
Study NCT00490529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard induction chemotherapy
Description: Patient-specific, regular medical care treatment as determined by treating oncologist
Study NCT00490529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC)
Study NCT00490529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC)
Study NCT02600819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablets administered orally once daily
Study NCT02600819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablets administered orally once daily
Study NCT01328405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Description: Comparison of airway seal pressure, airway morbidity bronchoscopic view obtained between two different laryngeal mask airways.
Study NCT00296296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin
Description: Dose adjustment to pre-established targets
Study NCT00296296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Dose adjustment to pre-established targets
Study NCT00296296 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 'Diabetes Education / Management'
Description: therapeutic adjustment to target ADA criteria
Study NCT04280237 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples
Study NCT00792493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: Alternating panel multiple dose escalation
Study NCT00792493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ORM-12741
Description: Alternating panel multiple dose escalation
Study NCT00262938 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral dietary intervention
Description: Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
Study NCT00262938 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: counseling intervention
Description: Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.